Low-Dose Psilocybin Mitigates Weight Gain and Hyperglycemia in Obese Mice

Recent research involving mice on an obesogenic diet indicates that a low-dose regimen of psilocybin can effectively counteract several adverse metabolic outcomes. Over a 12-week period, the psychedelic compound was observed to decrease weight accumulation, lessen the severity of fatty liver, and improve markers of elevated blood sugar and insulin resistance. Notably, these benefits occurred without eliciting any discernible psychoactive effects on the central nervous system, pointing towards a non-traditional mechanism of action. This pioneering work, detailed in the journal "Pharmacological Research," opens new avenues for exploring psilocybin's therapeutic potential beyond its well-known psychological impacts.

Psilocybin, a naturally occurring substance found in certain fungal species often colloquially termed "magic mushrooms," undergoes a transformation into psilocin within the body. Psilocin primarily interacts with serotonin 5-HT2A receptors in the brain, leading to alterations in sensory perception, emotional states, cognitive processes, and self-awareness. Individuals consuming psilocybin may report vivid visual experiences, heightened emotional responses, and shifts in thought patterns. Historically, these mushrooms have been integral to various cultural and spiritual rituals. In contemporary scientific inquiry, psilocybin is gaining recognition for its potential to alleviate symptoms associated with depression, anxiety, and existential distress, particularly within structured therapeutic environments.

Psilocybin-assisted therapy typically integrates drug administration with comprehensive psychological preparation and follow-up sessions. While the compound exhibits a low potential for addiction, its psychological effects can be profound. The legal status of psilocybin varies globally, with some jurisdictions permitting medical or research applications, while others maintain stringent prohibitions. Motivated by a desire to explore the non-psychoactive therapeutic capabilities of low-dose psilocybin, Martina Colognesi and her team embarked on a study using mice to investigate its efficacy against obesity, type 2 diabetes, and liver steatosis. Liver steatosis, characterized by excessive fat accumulation in liver cells, is frequently linked to metabolic syndromes, alcohol consumption, or insulin resistance.

The investigation utilized C57BL/6J male mice, a strain commonly employed in genetic, behavioral, and neuroscience research due to their well-characterized genetic background and the absence of hormonal fluctuations observed in female mice. The mice were subjected to a diet high in both fat and fructose, with 30% fructose added to their drinking water for 17 weeks, and fat accounting for 60% of their energy intake. This dietary regimen is known to induce obesity, type 2 diabetes, and liver steatosis in mice. After an initial five-week period, the mice were divided into two cohorts: one receiving 0.05 mg of psilocybin per kilogram of body weight via oral gavage for the subsequent 12 weeks, and a control group receiving plain water through the same method. Following this treatment phase, the mice underwent a battery of behavioral assessments, biochemical analyses, and tissue examinations.

The findings demonstrated that the psilocybin-treated mice exhibited significantly less weight gain, reduced liver steatosis, improved blood glucose levels, and enhanced insulin sensitivity compared to the control group. Remarkably, the psilocybin treatment did not induce any central nervous system effects, suggesting a peripheral mechanism of action. Further detailed analysis revealed that key lipid pathways in the liver and carbohydrate metabolism were nearly completely normalized in the psilocybin-treated group. Additionally, the researchers observed an improvement in muscle strength and function, potentially attributable to the restoration of leptin sensitivity. Leptin is a critical hormone that regulates energy balance by signaling the brain to suppress appetite and boost energy expenditure.

The researchers concluded that "chronic low-dose psilocybin offers broad metabolic benefits through a hepatic 5-HT2B-dependent mechanism, distinct from its psychedelic effects, supporting its potential as a novel therapeutic strategy for liver steatosis, obesity, T2DM, and sarcopenia." This study significantly advances the scientific understanding of psilocybin's potential therapeutic applications. However, it is crucial to recognize that these results were obtained from mouse models, and while rodents share some physiological similarities with humans, significant differences exist. Therefore, direct extrapolation of these findings to human physiology should be approached with caution, and further human-based research is necessary to confirm these promising effects.